Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

Guest: Alan S. Brown, MD, FACC, FAHA, FNLA

Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.

Host: Javed Butler, MD

Guest: John W. MacArthur

With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.

Host: John Buse, MD, PhD

Guest: Steven Nissen, MD

Among statin-intolerant patients, treatment with bempedoic acid is associated with a lower risk of major adverse cardiovascular events according to a recent study. Dive into the study’s key findings with Dr. John Buse and Dr. Steven Nissen, who published the placebo-controlled study of bempedoic acid among statin-intolerant patients in The New England Journal.

Host: Javed Butler, MD

Guest: Pedro A Villablanca Spinetto, MD

A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health.

Guest: Patricia A. Pellikka, M.D.

Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.

Guest: Paul Sorajja, MD

TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.

Host: John Buse, MD, PhD

Guest: Jennifer B. Green, MD

The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.

Guest: Ana Barac, MD, PhD

The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

Host: Javed Butler, MD

Guest: Ana Barac, MD, PhD

Cardio-oncology is a novel field in cardiovascular medicine that has rapidly grown over the past few years. What kind of role does multidisciplinary care have in it? Dr. Javed Butler is joined by Dr. Ana Barac from the Inova Heart and Vascular Institute to take a look at where cardio-oncology is and where it could be headed.

Host: Marius M. Hoeper, MD

A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and explores how they may impact patients with PAH.